Pharmacy (PHAR) Course Descriptions

To enroll in any course in the College of Pharmacy, a student must be accepted into the College.

PHAR 6110 – Pharmacy Physiology (5)
Fundamental principles of normal physiological function of the human body for the pharmacy student. Topics include all major organ systems and will include the relationship between anatomy and physiology, as well as, allow for interpretation of pathophysiological states.

PHAR 6111 – Pharmaceutical Dosage Forms I-Non-Solid Dosage Forms, Lecture and Laboratory (3)
Physiochemical properties for the formulation, preparation, stability, and performance of non-solid pharmaceutical dosage forms. The mathematical calculations for the dosage forms will also be incorporated into the lecture and laboratory sessions. A weekly laboratory session allows for application of pharmaceutical properties and calculations to pharmaceutical compounding.

PHAR 6112 – Pharmaceutical Dosage Forms II-Solid Dosage Forms, Lecture and Laboratory (3)
Prerequisite: Completion of PHAR 6111 or consent of instructor.
Physiochemical properties for the formulation, preparation, stability, and performance of solid pharmaceutical dosage forms. The mathematical calculations for the dosage forms will also be incorporated into the lecture and laboratory sessions. A weekly laboratory session allows for application of pharmaceutical properties and calculations to pharmaceutical compounding.

PHAR 6113 – Pharmaceutical Biochemistry I-Macromolecules and  Metabolism (3)
Structure/function relationship for biologically important molecules. Topics include anabolic and catabolic pathways of human metabolism for proteins/carbohydrates/lipids as well as the function of those macromolecules in normal and abnormal physiological function.

PHAR 6114 – Pharmaceutical Biochemistry II-Molecular Biology and Pharmacogenetics (3)
Prerequisite – Completion of PHAR 6113 or consent of instructor.
A continuation of PHAR 6113 with focus on basic genetics, regulation of metabolic function, and principles of gene expression. The application of genetic principles to pathophysiological states and medication use will also be discussed.

PHAR 6115 – Microbiology and Immunology, Lecture and Laboratory (4)
Fundamental principles of clinical microbiology with emphasis on prevention, control, and rational management of pathogenic organisms. Additionally covers basic principles of immunology including: cells and organs of the immune system, activation of the immune system, and the role of the immune system in response to infectious disease. Other topics include organ transplant, autoimmunity, immune suppression, and hypersensitivity.

PHAR 6120- Introduction to Pharmacy and Health Care Systems (3)
Structure and composition of the United States health care delivery system. Political and economic issues are introduced and their implications for the practice of pharmacy. The history of pharmacy, its role in the health care system, and interactions with other health care professionals is discussed.

PHAR 6121- Professional Practice I-Introduction to Pharmacy Practice, Lecture and Community Pharmacy Practicum (3)
Factors that influence contemporary pharmacy practice, roles, responsibilities and expectations are explored. Includes medical terminology and commonly prescribed drugs dispensed in a community pharmacy practice setting. A four (4) hour weekly introductory pharmacy practice experience in a community pharmacy allows for application of principles.

PHAR 6122 – Professional Practice II-Public Health: Policy, Prevention and Wellness; Lecture and Practicum (2)
Prerequisite – Completion of PHAR 6121 or consent of instructor.
Principles of the United States public health system for the pharmacist. Focus on public health policy, health promotion and disease prevention initiatives. Population-specific applications, quality improvement strategies and research processes utilized to identify and solve public health problems are discussed. A four (4) hour weekly service-learning practicum in a community-based public health services center allows for application of principles.

PHAR 6123 – Research Methods and Pharmacoepidemiology (3)
Introduction to the statistical concepts and methods utilized when applying statistics to health and pharmacy-related decision-making and patient care. Application of principles of epidemiology to the study of drug use and outcomes in large populations included. Common methods of conducting epidemiologic research in pharmacy practice will be covered.

PHAR 6124 – Patient Assessment, Lecture and Laboratory (2)
Introduction to concepts and skills used by pharmacists to provide patient-centered care. Patient interviewing, medication history taking, triage, critical thinking and physical assessment technique development are included. The application of these skills in pharmacy practice settings is emphasized and reinforced in laboratory sessions.

PHAR 6211 – Principles of Pharmacokinetics, Lecture and Workshop (3)
Principles of biopharmaceutics and pharmacokinetics including calculation and interpretation of kinetic data. Additional topics include factors that determine drug disposition, design and adjustment of dosing regimens, and prediction of drug interactions.

PHAR 6213 - Pharmaceutical Dosage Forms III-Sterile Products, Lecture and Laboratory (2)
Prerequisite – Completion of PHAR 6112 or consent of instructor.
Physiochemical properties for the formulation, preparation, stability, and performance of sterile dosage forms. The mathematical calculations for the dosage forms will also be incorporated into the lecture and laboratory sessions. A weekly laboratory session allows for application of pharmaceutical properties and calculations to sterile product preparation.

PHAR 6222 – Literature Evaluation and Evidence-Based Medicine (2)
Prerequisite – Completion of PHAR 6123 or consent of instructor.
Overview of drug information resources and systematic approaches for critical evaluation of the medical literature. Problem-based learning strategies will be utilized to assist in combining clinical expertise, patient characteristics and medical evidence for clinical decision-making and effective communication of information.

PHAR 6223 – Professional Practice III-Institutional Orientation, Lecture and Practicum (1)
Prerequisite – Completion of PHAR 6122 or consent of instructor.
Orientation to introductory pharmacy practice experience in an institutional pharmacy setting allows for application of principles.

PHAR 6224 – Professional Practice IV-Institutional, Lecture and Practicum (2)
Prerequisite – Completion of PHAR 6223 or consent of instructor.
Exploration of medication use processes in institutional pharmacy practice settings. Technology, patient safety principles, pharmaceutical compounding (sterile and non-sterile), operational issues and formulary management are emphasized. An eight (8) hour weekly introductory pharmacy practice experience in an institutional pharmacy setting allows for application of principles. 

PHAR 6225 – Applied Patient Care I, Lecture and Laboratory (3)
Prerequisite – Completion of PHAR 6121, PHAR 6122 and second-year standing in the Doctor of Pharmacy program or consent of instructor.
Application of patient and health professional behavioral science principles, social issues and patient-centered pharmacy care principles, pharmaceutical knowledge and effective professional communication. Laboratory sessions will focus on immunization certification and delivery, basic life support certification, medical chart review, patient interviewing, medication therapy problem solving, devices and OTC product selection. Issues related to cultural competency are included.

PHAR 6226 – Applied Patient Care II, Lecture and Laboratory (3)
Prerequisite – Completion of PHAR 6121, PHAR 6122, PHAR 6225 and second-year standing in the Doctor of Pharmacy program or consent of instructor.
Application of patient-centered pharmacy care principles, pharmaceutical knowledge and effective professional communication techniques to solve prescription problems and provide drug therapy management in ambulatory pharmacy environments. Laboratory sessions will focus on medication dispensing (prescription and OTC), patient counseling, medical chart review, medication-related problem solving, medication dosage forms, health professional communications, medication error prevention and administration.

PHAR 6227 – Pharmacy Law and Ethics (3)
Prerequisite – Second-year standing in the Doctor of Pharmacy program or consent of instructor.
Federal and state statutes and regulations pertaining to the practice of pharmacy, licensing of pharmacists and supportive personnel, and drug distribution. Case law, standards of care and the ethical dilemmas encountered during the provision of care in a variety of patient populations are included. Issues relative to business activities and professional ethics are also covered.

PHAR 6231 – Drug Action, Structure, and Therapeutics I-Introduction, Lecture and Workshop (3)
Integrated pharmacy curriculum for disciplines of pathophysiology, medicinal chemistry, pharmacology, and therapeutics. Introduction to pathology and disease states, ADME principles and drug design, receptor theory and signaling mechanisms, and logical patient evaluation.

PHAR 6232 – Drug Action, Structure, and Therapeutics II-Nutrition, ANS, and Cardiovascular and Renal I, Lecture and Workshop (4)
Prerequisite – Completion of PHAR 6231 or consent of DAST coordinator.
Continuation of integrated pharmacy curriculum for disciplines of pathophysiology, medicinal chemistry, pharmacology, and therapeutics. Focus on patient nutrition/fluid/electrolyte requirements, autonomic nervous system, and therapy for cardiovascular and renal disorders.

PHAR 6233 - Drug Action, Structure, and Therapeutics III-Cardiovascular and Renal II, Lecture and Workshop (4)
Prerequisite – Completion of PHAR 6232 or consent of DAST coordinator.
Continuation of integrated pharmacy curriculum for disciplines of pathophysiology, medicinal chemistry, pharmacology, and therapeutics. Completion of therapy for cardiovascular and renal disorders.

PHAR 6234 - Drug Action, Structure, and Therapeutics IV-Endocrine, Pulmonary, and Genitourinary, Lecture and Workshop (4)
Prerequisite – Completion of PHAR 6233 or consent of DAST coordinator.
Continuation of integrated pharmacy curriculum for disciplines of pathophysiology, medicinal chemistry, pharmacology, and therapeutics. Focus on therapy of endocrine, pulmonary, and genitourinary disorders.

PHAR 6321 – Pharmacy Practice Management (3)
Prerequisite – Third-year standing in the Doctor of Pharmacy program or consent of instructor.
Introduction of pharmacy operations management, pharmacy financial resources oversight, personnel management and human resources, medication-use process management, compensation mechanisms for pharmacy services, medication safety initiatives, error prevention strategies, developing and marketing of services, innovative services provision and related issues in professional pharmacy practice.

#V\2yW;_h˂sORm V/m̅쫫 qf%f׽x)+PֻkY]Wko$UoLteЁɔ$T&+% i2la_;eak/(E9`F`KKٗ&)У( Gr,/п#mYq ,sA.ɟ~nĶz(oy菃U&2 VP_PŰ2sό˞;U3:AﳠA!-,]o %I B脾|AD<0}C&UsK'NETc@ezK$( XG>IwR:5LtfX(.l@6 z$(\/C+ޠ: GБLPMTKc+){*5BQ13g#koU|pwǯD1>R2?0+೯`(F>'}*Lsܵ/*>pun#s7e< m4V*Fܑd;FJ}t1d0 KkJe/g4R*qNe&ы-QJnl6 Ud7gS#J$B!|bѲfdU'@34 ̲U(vn*4޿ \" 0oġmKg7tWhmC+OammmOY}h}d裏&!Tzk֐]>;>ݹs/i/w0mN> Pojmj=y#oyן}lmV. |U218L9Ys?c^}Z̬̑\+&%ΞkN{{k}x v NJ($5"}-da/+h 'q>zJg~2BMm[Q r01["g4H-5J8:c[ s&2c(%0p$|-@v/PaC L`[aaL}KwBLد3XfW|֕iulZ .-;^.}b&vBfzng7K];)fN&|bHꎕp zQ`3*T+PB_x &(%e{ gzZDj!}&3,~9`eoT\bYb/2Ĩ%3ӹ &sTQ"ɮLc3TR.J;(_/B 1hK!AOx'JE|%tBF =sYhTWJp*~YS?J=ӹߞB^#w'4j嶠~c}h9UF9|E$sW"!Ew9ym8Z HW5`7x$L\wu3gD*On_;љUpǔq%"$FYǥHT>ΜIt61Cl;;wd+B/~ '{Uܼsᢌ t\V%NE!I58|dCZ>J0OLڊV`' wB ,#*W[+\-U` ?*'/I|`mXnsl3/lfM] jGM1NW:*o?1ZZx]1,=`.r6Rq4ɷށ 1ހ93U=v*׉U`[4A.rV-(ƽ0bk.zAۚ]&lhMf켚9JRK, 97Yu_Թ>'Qƞ 0{"kZZ[FlWJ—]sGpWw>6wÍnZ 33'*؟DʈI^zoI~`HO q,=Zŵ;?.V#6ݭL͝vܑw bPk'N7wzDKoCM6WX< (ZAf/ Fw#R'$8 O"@9u#7i# LEgbN¡ Ä l4_dڌJ::I9q&ll>p>10,r/]_i>d;RNRv?T5N;]iC>H Y^G>(^[t"5' UT'g*vU[A@~g`s9gʧNH&24-1*gY_vn> 8_;e׆[}J~z4NWdRۗZPIGX䈠a&sr_YcuxaؕMΔg 7e Z ͅ&;^RjF`1ʬgvi3uk+`y՚Zݨ-4`¦d[ p]/-c|0🗛7;-ѐVT7yz2jrm6h!]NHmsf/3:g.B˅'m/7y֢.|ցm\[wg?ى}`h4gR怉Rn1kPMսq]]=ŦƦ& :EwW'~& n_w5^H: =C <%Jr(󥝛I#rq;WkXB>`z Qr}MTGIAhCba%|W gIM)_S™s HGzEz[އɭ pT|VPbL+è$@~sdeT9VcZ$C I!:S$# xΐZUvdG,[OMߣ^ۮ\R-⌅dV̢d>[z& *iTa''LX&%(sEIi`$dپ\PG47h]wy]WtgF5>yLoo^שIMsL`gәr-grt,o }\N7#Zb׻{wͱ+./'U90O9H>Iq5|d .+᪖cؾiX"Q#ziW7 T^q>na?=w;h&>c}Mh7 J~?ʿ`qmj^+W߫Wy:w\uD~5Oy7уS`jΣ5L"A8݉Sd0r= ->S{CQrow!?>Kd&m̈A49$)뒥x <&}7o}#+lO>Y 2k∰/ɘ刋[2ax|%kL|˽K/#//lVƁ|j)m~׿U{P>,ױRd4 S1Pɓ,PJtI/V0βrKa l7̥>묳y+L D]ˮtC@ Kr  p2elry"I/ ۛ)6*h]/2-x ꜐o% a ER΂ C:W# vp3dW:)0Χ^d_@E|d~0*^RHȴ-!كeRΧENf: y .SFߝ]riXd#ZO66ܮ`!m뛻1+È8mWvEZ2kA셝sw^e喳b䰆a-uob[gnOjIP)$5o9 9#i;̓q P\MR@ZpG٧œQd)WixV~7f!fz _$!PGŬLU-r2Yfڴ93ɎDLxd ,EV^T}@QS \PO@TkO7aD㟊'ST=tNLeƈ;S OX2M84>K8b̴x?ndź|#HHU/[Es 91f $kgr$8-CXZMo ~Y~ F̊}ak?/~t1q5< ;m#1i5< ?ϣK%wG[>50DICfim_ƱMҙJ.+)gVarH U'g=u&WC_xcO}g= 3;RtҘnA=9ӵxOqk~G^0鳷=oLٱ;-\c; ֏tr/G`fV|;kw])xa%0`2,+.---^xm=^xWKd ͒?ᴳv9@mbb3An ho{;I#QM/KmoH"~„ %ϛQ>r g.!C\qn9spp (\p"orA3bc1[dRPJx9="#=-ȂlJ\/𨎀Ѫ쎝Rq.xE)q@: &0B**|aM9fF_IRI[9:L =S&K/xaʫ3 9Њ*q-AъՆdZFbc%73Yg[?mq%m :k2n]_[2ضuaW҂<^k?j[so#(hDiqWLtKE."`{N,pEOP[UD^Y_2b4Pb4lEK4_4]ǾDʡ\h~tۮ[pG/\c˿EsM6YL-o'=ȗKsr:1VQ N($yOPW_M}mM}MPCBDrH0 L3-Y+ }U_R>͗k*/K-R RƳ^Y,Y^IOr=sfJbC`{ˋPqsTM"#TGt~kR;cvYTu񬹥n^4sN{O4.k,BFD9%f'Z%,VP9WCj۟dC(ĚӷTȠņzbBR,Uةϑ0T*d ta٥G)!ϟ8ΔO+_ʥ5*XvC6ymڙO3+'}e]eRJTnED"TӕP o#(/JSm9%c}K'j 'j:';MNA4a餢v"l r ɹ-vq]vy M[<Æ >Z:we]vFJKz7_ŇJ[?n_r//pO_xw}鯼qGe1|0skS2~+@R-fϿӋhbik7wDx IC u,y3nnmU HEmoFfz.pFf޺afÉ='?_3fwy@E[ a!ݠI6V[⁕<κ&`Lm>33a`H8?m,^hy{N++&ϾEe,Pf)Yk1@#jg:GJD>pWT6zں1N@ۧzV]?m{t#0~?@\lu M~ ~|HڂoW!D sN U!瞯}k_z!H 0Ka-qGO6g?TE稴ZI'׍ku9r$FS {G"q><Ȧ̫H8DH ^~eèrx'"M ABHqq7|ob.d& :ƺ;j(C~\ve *L:" O"3τ,vn@h,)yu}W`/opL;#<: _x pѣFC8 O7 m>A·rڂ߾ozE΍7Ŧx㩳!a4)s饗u~/=͛GRK;}_à} ,"3[o=(1E9'UjFJE0d(;D&  # V%|nv5>o,?E*v+DD*8_ }T%0xT116~t_EWgT#iSyo-\SUY_r (bH؜[ ($l"gxߦ1;+ \u fӕ*ʧ6hujNи_|(3J!y LX?ڦOO:kQĭ0:kFʒmK,Ağ~GK|8{EwSZSj/01=;ww >{n;ECD@{{+ʘ{!T+uc*f"lضxI{Gg:2Ft@]x՞L+RG~foˋ<ѭl z ,!O>l\+ͿoOwcVw>8CBŠ+j&$ %&=~ 2bB3qKzCh|WpofDjffc O\|-@IrJ I.Vh/򇅚հFz!](I` =$y^m1},2G%JiIqrE3[Y*SZfv\WFҋоSZ7_ A{ ݻnب|G d-S۠uvTBwJi8u2-vAX)ͪjql]uC3;ǢOZ;IX{NTjy~U 1L+E Lf ۽ݴYػ[9*Ɂ?q|4`O\ҌF1:$.9*+]%8fBAQvO¹87PΣԴ_Jj[1$ʧʍ MPAqY[N)xG]4zo [}_tG1#w5:# pXa+{ME]W' `Vjl[Јޛz^{UhbqO:@ _%nz-C}Ui& r7 f"4YOrŖ\ a];1_ p#:oAOa-KRlY}5L|w͆;.9dvӵ&x͙3g}믿>^HvVR}$>`>N)4g:!=3L͏'}ھ_+)vz 2ߜޭ҅tIx6=]Hh+Wyk(a2J97շoq_]>>C1KX:Ttޑ_ykzK}Mn-FcAv(c>5JNJ s{%W}؈s57/׭℣q͍]]&k%:ov/ o#T9nELAzg~uw9^!'.민JFiyh"oFJZ^aH;^TG0`ǃC1p @6@YfQ oVMQvh$BDmV=g>gP~ė_ˆQA4Th袋 `r8Ĭ *9,ڎikp¹s炀1c@4/@LOz?y)=뮻8U X[nm6KNR { *W S{}- !w0il`ˍx}Q jj>MnfQ57 -9s&jD vqv9R(1-u䃇,ӫqH}| 3F!!}HL>ACpn B~gZ+..7'JUV_}uI`'yLO& ĽDJ6Cd+[gB&˿[=Ro|4 z eibFZЮsY{e턊H8tm{2A$[J0 &s$/T~W SsmOʪF\6'}}dߜnM'|a}]Bl&q~8f Bƴ ;;_S>?^%`b( pU's羻1(g`D`7^<>5b{$P #ALؒFjr5^ytuðCrh+oh&>g%Gl~|:Ye?<%>6"ZKj嗏Ql ;\ cΤ?UVۊޯK.]zĵ8KKj=-5;`ݜomoFfm`b! s`zu4~rm޹"*]az+Mr=Gj_yz SiZQ9\^s1+[|7Yuc ґx0s!i:פ.&<W477!xeF@Y@ b Gz̝7p"#s9Ȝ3w'0o>̭D]da;J "x߉$u;mmmxyu"&Mp lAOv*&HTd0\u1D?蠃.GU)SmDoP(6xc.r8ĉ6`K|KeFi^{5 ?\BD§~J'%ݦ48Tو1Rf`/{K}L_K_(Gqتx i@E'+_K iC+pDUFYiE!0{ˇ3pJ _)5`6>%u,cbKcmR\}مHcvQ?U 6pqbvh}RdIeo|d.b޸1 t̙Ӂ8,zwڧ/M}okyܶ]zwvo=`n"s6ǂŶYpN/)ԖKy/=k^cX(4$t|^WNjʥm ͙3oμs$ /?QggӄJ,j赲 &za&e~q!5O;  tE7zů|̾*m|phzVsSX-'plQD^9#w'-l{ݢbmŦʵwrsKzj/v[f/y}sg^;]EDH FaDofܨs$dK~j}y:(@3o2w ͬ1<טfO'חoNhJ@R=k,X_~>#޹Ͽ.۽ :;ims-ӌf]^[7cAQU_n}gsJ?Mz k77!Sܗ,f8}cfsoh^Rr,ʥ[z\3)E׌R8.%IPi=RNٸk]sonCE8ήEs}ܹ;Z\ȧ#9pRu>wtC&[.^dUKfaOT4k!SJJ- x\||yZ ?n s{W/qق_4 /cm-Ю9}t&Ͽy TAbrB<%i'C] g^2}n:_97#9K}LiҺmF[|bVn I>  {c8삕 gTDJ mV4gAA"_mKwgն1}؜v;>0T{+8~I=@b`&P$u \Ii!NM-K<,we ZZ) 94AjQܽ`A O}þ{>{U;o߫wo-6c~wךMgE-68q?^XĮg69陟OaGYMὩX.Z_Bo_{3!G~ht/xx&N~8T<>\Ix>v/oR3:;~^`$aɐi!` w~$#Ǥӧ ^>~I{^^@t0ib&®\Maᤗ^y+42-1gm*!_鸦ݔܿkOn 3xAqx7xs4^ P/El_VA:%)x~2*'L6+|:m!Fy̢#~SKfU8ۊYi>r tr`ݻ~tKGn0WOm !bTseↂ}cS>὿n͇6{wg5nF̈́&_v/>!UW[hǤ{…|:w֌ٳ?+7%%D< ,=lBl]lh_4nSq"m- |K'^j/7J [Eᔒt3 s$2ʹ5ѓ[+6Y?g%u7(ςr[MnAzȄrEyb2joQ},] CbnZt%W` \z{Ux{G*O[s@2Bُ/?c:(]z#zGzE~6@V(*(EQPAD$H#7;{ssnRg]7o~3;;^ٻyxDC_3(|<`v{Q])tn:(Χ:PMm*2r%}.A!XxsI%\+-z¥.J4pcWn5zx_f a{n5`[Ob/p"+q)!Kq?E%mhR*2fQL8t]ˮf&`Ƣ5֝U>O0kTSbUPv%cFtJӥ*D' USx*A"H4yBO$sBD | |;O>D̅ pֺŤtDHSv <]^Ԕ` )O{y䱟^fl^]Y-ڮFMN#6sRе燭;_C(ὖ մz+USw[Vk ǟr=/'g|eC㮆4>hٸ`_;{aRPV= .x^Kaq ,om6ߌOy=h@ B ]ǪS]O͞o,YCT˻7WzG)7b58bm,!m\UF'd7iJIa![{=Q[l6M[p |dK.O~! W@Wmڴb[7|'@b۶m!FSU 풤i;h4U+C Zt]DJmQkMXrӹis&.=j׍ǿ22?+B:.>([e1gJm0OvCY;rbsA.t0d!? n.=%I-0>ԫ;==}@100vP 8 l pH*2>>ޭZp d\Vz:Ajh!@;94  gR_woݺ5o0RhFAӪA<].[B3@ Hz-&J k < ?U`Px5(0 e/.<@bLL _JdKMe˰ l |O zTjϪ<),F1ny؉E8w &u0/nD "hrHBD ZQq?yd 36gB'F3d%Aa4o Du%FtA\hDHQt::WP̥JĿ%9Y| PU(l 4{QA"()=zCW𷞋{g3~K;3y(_л6p" ruyfcmh0 n|'Fo"q6@?=1 \3C ]0"EKPSt0RQA $ 8*Ah66cmxZM@X@-mDFcZRTj7O#&J8(kTz dڶA{L" [H_\ܻ݅ʖ]Dc#yΔtlT-"1Yj =gɱ%l$NLJfCĖDz)A]zѯ|"wؙBTI_K(%oͯ][=WfHhaK8wnaawzuˉ/fVk'vgx8IW"N-gϿ$\q#OڇmRGtx).To3NAL4r?>&XX@c6o &^L@"p#` #TV pgϞ=JWpF5](O~sQj*UŖƁƌΉi8-# BUB;XO0^u0'I ̜]q{s9JeEQ$ _&܄G. SWq48ջ]n SpP",|$E@NWƨ]]8MHRfZ M:tym~%˾~ʇN8 2_ :4 ]RهXp,.R_Ǐ ĉa5@;{Od`"ZPYg"aNp ,gP)D00 |[ $'K 7o9rŋ,(6a@"0쭎Io6i4ri ¢E@fҤI8.?,T_\y"Hk:gpɥ"d| :Qv%k<ƄN׎^:9W*Ek"XDdMr ' ]Kd1цvu\(#v;.iCIҵ_˫eTHvГ"#VdsJXlO:Q4:p;3=pjC5}~[<ݬphXC߶1wm!(ȷhTTR̂y+yNpչcO5Sߠί4_,ƾ+IfX/y&[2c-= s9~d-`f%%E:p 4zKԒKd,LĜ;ݨam< obF h~ٳGuq$KYkNjvz?-ڏ=W=?/cCP?1.$ZZ$ˣnmMO]Rd.z+g,4l6(^ZWRϜ=.>u% b#7W/1趧T7d/ӥkIMr?sf4l Twãi}(oCHٗ_NQ}ǂR 9sS#™#=u͊Q}qef zw]ף =ሷcُWK) NE\R ~4w.aa҇ 4Ƣ{Emc L9Zժ3k ? h?1V7s&Cʆ?X4 ?c lR=$W8n06T}dJ@1ӗ\=K =9w< z/ 4a);?wC ).cv_W: 42fs,8A&X&3Β~nK;P3F7`9нz6.W=|pP?УZٴt p,vdsw۞6ث:/?a@~@AfcWD8Y=Ļ|ݖ >:C} '(1PH @v8oMVlIr:z6rEF4H%ݏ*m4tR`-eX hG,Y"Xd#4]]*SdۚCfJ=DxgUԪwNNlYb!>NJ$EY.rEY(K޻n,eW ҃(҃GriDj6".&cfh#4AtL`4DR,;3&*Xz@ؤ ;]] ؑ^k@حSM',F|/q{$`Coe Zݵcm.NjX}K^XO$<:z bn1(hĈ0λM)]K=*=O? |/P?'NLZ"xem&WӒ]oJ=+;ʉkVyV0')~0"@'XnfyyzVMEׯ^U`-pZ5/΁4#ݍ= : |D3%>]%|Y@ƢbA(V@6[|? XPᎍ.o+? c#0r]uRO*-ݩ|KtBPv`? Nd'Y@(>z>chbkW@KeE.swM/GGP[U./ Rcjj,ӯڭnKk=4"xUN9AQG/NMY+>RefW!aTR/I Z%"x Rrn5JJ-T}i"6fI <h&+{4db(ڭa;ʎ5ef`K3V䶇_-ۏV 7Mco7?ٱUvsN[^n{Vs.yU7^m(˽yH7k SV@zu׫[nzAu6n7 Jqq ƒROO/psd5jLY? U%o rΈ`&@=#p yxnȔ5^mv[3o c xy0ߢRbx"#/@Лp0SqȻ..57 ӝBsIW ^XJK̍JZ KI7oW7x}yj PǹB x@@RnY#FM6Ea;m\ĺQ=J~kxy{-ZtY>ڪn}ndzm})5I^ڲ+)ՃbOdbc.bypDB\LI/`Ue0[ .4-鼣J?ћ aIlԛ[Ȃ$>E6gR.@@q:F$1ph|l]Zz򫥅8GF=t1 wWdI^ 7XX >|+|$(#@ 82 yy)-I1ֻAbq$O6r _z譃__tYj/5\^riRa+b#jɜ&(;L+;!R}A" R:rJšu*E`femPҬKPB*&RJ{ e刀>lyTY˵ry*v>7JrD]V+-B" OWh9؇%܆uDp.!lJ&A7z0 A8#3 rf+qf |rI1}.,4_9J=71[BtǑޭs.7_ Ǐ_ψݾs;)7w*H{7o[+N՜lW7pqmIoAilt=Hӥ&S 9 8U=g!º(S\ F< HέѠ01%@p&^2>&^w~}XĖPjϖ;ǮuUϺp9nnֽ3%<č$؁$;>jm[!k2S'Z/E)a"O[ܠm-^(ŸPN`K)Vh}UEǡA.\O.{*Hp]Q^Xqu~@s~\T%V6`YKY*ƉdB'*d򗾨ɘIn"N_q~܀f\mK7D!r)L"Ii}R7*@Hva: Hkx5j5gS0g࡞M8wW<r~58ȿ:((AWw;&=Z4orz,qAcO/x#p4ͤ$pg{Թy]\f"T 'j'b?~VQH!$K7CDU?{k=otЯ~7Ol(A8\JLp ^@ ;[ I=~jt[29RA!9HsۑF_nRtvnp | ޗg1? qA j V` :g| AS>A!`ٱW5/vs>|0+bta'ۜ{rG= "׿#o 7aǐ:@6 ư+|NbR, $EWz~߿|<m;gu_n> 4 HLՕP<RgNf(<+!`5\tE?b9`Mr9*nIfc %2̦ %s:<]|Θ !$G @sɨ,]}vgWK sV? peqԌzSQ]^jGz8]!9`/1Nܜ{? Gy:涜ۃk@ oM*|` 5tĄ Gdt<;w7e&>0q'N v DT3Cxnhų?'\'ZlXlOjҫQaE={׃x(&Iٓs\R,r s[ M nÍϝZ{"x[ƀB!07^<77z x 7-Ձo@B d=8(pA n(.Bvsp?Oo}!T `:@T ~mpy ʁ6+a!_zvcrTmʏ="he:$Bec}STBJu^Ŝ@Y4V bcƌ 70Q^TFLbvYP/5R)WA4xie )$+C%RvbJnv G5-.{t?Tv{f8嫈ը*`baS*SJ7S*ÂrPz&׬H›bHcսt#ZrOu,m^t3.foQz1V%pH'9j$9/?0>cz52Ww|B4T ܬ:M:~Fu3v޵l?}k6xp䠼<āVa_a{O256쀚+ԬyڭkNo.m(_fǠc.}YwW\Qfݯ^N_~-^ |umڇUݒ!< |T˕MT\j2B~n'{PZ3L*FaGLF+5®C"ZGQ&߈_=.6߄No[9'K6yRm)Sg0+rDA\Q7S/ꀐ )[ `IHj4neKWB%+c*ޛ>֧1L}wnC<.qDAvPYY/>FO\mui?%/Y]>&}+KaR$#;P'-cM˦kDU|9 yǗH5=YOzxo)wDl[Ĥ`:F: յ)]4Q I'0%!$xgd]OZ@U&!r)Ӝ΂nx#w:O:]4hK#s  |/\ޥl_U/VShi7#G$=[Iwvu陹};v -uBo%F?$_ {Y*Ҭz $;C5!F+٭ HCrH ѷ;D5Fw~)E!9wui4-u<X]+~imA`ܹsĒvm۶m Br 3G?V %~,<`Pp.}ٟ*,ޱSgݻ!9Mc7PL*,H_P%CI P"n[5+|kzx#ʫvYDE#~4Sqݬ (w*u^vIGٮ%:-/z+OvWpEá1-Q-XN!Q C\R-Is0еCC>.eHWĖ@_GuCf8r#tbޛE~!M}ׯoժ,jdmӫ,3M@HD21:\D2~8+;^vٿzu%:u"@3q"I<$ì+I“b7ȿ5i/ =R+4nObjm1&. = =Vl TؿK96dO+tpP"DtJ#;W ] ٢`|.(bWD| ϓD| /`5NR\@z"P%+ׅ0c"@t`X`QKemV2٠-x ;Ԕ,I-)H>Fx۰<6IN% -DIJ$R %$VVE:0Urҝ)˪mDlҩZ`b4tk݉(HLj(?˥N+kӚU2˨\ˢSJ8mlFjY½F~ctOY~tuOg˓?2?bq@EO)(gfp;rG!" [c 8FKplx`'ut_` ! 4«Nx!_ۜ X쥊w^ z$3ͮQE}U*ꔔXTdȓ(N߹eΝu~kzRo-. @HzlۓĤǒ7)OY~}r= ec%@˽4Kԕ҅l)mB`[KDȁ.Wٽn+z7??vJ?u48#UDC g.UN u"LѴ6}#S137{X}B%Iٷu$G={!jR1OTkt\[hC<"1صGzJJjsV0ڝR2I8R]}$*k遲2֕ox^uѡ#uEht \xI777W7wwWw7nO>P  $M(/ ,12L4t+9xLSsllqt/+"e;N[lVtwEE4]B=ݻjcDch(e=>˕cʨ,#sED'OWfTnJTwXuBgfC.Ko fƾaeE@K5vZdX<pL^hKdK2ԓ;@+{/9k 6+[)`xeD^$ht ,i?VpǏ6OdDjh}q^JzD-nIv): l^ߎ7" .MFz'%\ @wxQn6}ȑgϞ%۷osNN=L4?RE^NrMX4^\V|md X\c[5eA{){8:ȫ$K4]^BU]2ϓ'O-/jB_8.nIE'pAKx>yjx6m}kكMo@8*D L05W_wuҜ0W1MixRI"3BmtC9rŤ2.!;w|npE;L,rF Ό?<Ƀ[xYx@y(1x05OxD~ =zt(04)nIXTH#%՞}}^{Λa5wx;bXL ^RJ􈡒^HIt:tl(9+_IV-O9-Z#Z LWJ.k A0Ѡ4< 􊁍b.AXH6"SfMT5ESԎ+Btٮ4kV3EVI)ms^Y&ɒb@UKOz1|؎ER΁ZʦW*d\#*֓NuUVɅ'ߩ}P&RQm_E_tM ,ju3KPYZVR;݌D@ +Z]ZK)$<B{!t,< 1I?B^<}CbIϓGql=J{viLXV}qx@)VVi=[Wk/g}P-~"+&Q!RPCTMA4 ]:On~<3X*;/+N~TgQ,]@C.!RD5Vd bO>MVoxZ=9A&GH\?ۻ!V< D.tĖc팼z6&@ &{ʐm`/-M{Y%bRP* qUt;[m}<X7/\ZjWv&kOZ{&|?KG@DC+4)o?hے 0nG- YY=xt}ߟu?{R;DH5ڷmU&sZuvd~XFY5 DGsxkL*N)[~v OPp.Kj7)i6 ()M)Rdzo" N&WL;d̢Mdvp Dj{sa|T!;;ۛgK t7 "`fի#.Zyɰ8%P+<beZރ }v||4U::HE-gB)1>D̽MZVkkfmo"o-KPj׋wc Rp4^"57xkI^B8/fO] h4Ir[ѵ#,IvSlK"DRcqHL{DMYm3]Jx)#NS?uS:/ o5mP%0; s0C!`0 CB@#oM#'?D& 5>'Z~iAK5U%-ER0爥mHDƟg&"O:~]Q^xiD䘃/< p2k7# ܮMWB* !ƿ{]O#Fhq$+fH޹=v>#0a< 0=J*!JaYRB2ze< 0 ^&8b@* (3T ڬˏTjYʖo"{1ۑ&e…J]_%:YYD֟9FFb(!M l) JFKDlrVc(u}XN"HI Wʅ x]ZNKQrHZ%z[+5R ? T&")5"hZFeW){&G0oΏUr!\bv6\]E?DQL(+vWRkRkѦ$hh! 􈺓H Hwꀼ`R6ogH6ˇ2: hM,D+ZWm)aYuH֎OG|@XOhi$-GaTF^uQ@jSW]Sejk')b0U,JٓȘ)gs g>/|ϜÔwQm}V섈t^I˂'NׯM6_!ù[!((| +D]2ar!aQO8|Ǐ(&Z䙀;[ֵ}uj@ &\Q xc8 Gj-:Zl([~^allŋo޼Vnݺr t@cZ,X?Ѽ-# hvL ~Wrzę@~#`5`/2?)B"FRj2m9@ ǁ4PzO*tu]*IH_E麈2uj9UH&S ԞA-EG%h@fI*eD;[hHŴ,mJD3q5~mjKYJmJNi(2v ԚڻMةE@i*~P!%Ok|j~h7C P:v u(/-PFllORʹ΂Gm7F 'E?espM8eq$),O-QKN%*)u-͜*"ZEp9͹Zh/K~Y1Q"yҦRi$Ůfѕ14 RmUk׈¦M‹Kt6ZdR.gconRY0n#9}K"(YT^C *)SKgᡢц+ghG_&lZ;hL @tW PC "p_ń ܫ_f`\v=%5l*vq]f͚4"Ӛ.g0:;mlpURLKvv΅ cbb!"pjժ\F TĮ)TyIS<bGl,x@wwbs!Mu.EL{' "ē0!Ha9<; $Pk@ w/Q8:p!|.zѳoνB-TzV+Zv6DX&O S*#"*sS–UdfWG[-J3MEgVqvI;ӒKԷULr%.iFAZJsEMTJ5կ^!4vou[;tof/qTAiZ ㉞gO:]˚]B妯m-e'zPңL-: y֥D3pR̈́X>?鍖! ͊FqFPQ$Kdʥ`YTT^t_mTԷ鳢bv,~=O[Kc*ڴ6kIyΝLR? x{{cHY\r-Ãh@Vi#QBOKA1UQ]eLcobyѝ4Kt@˓Qt@ ҽBvtUsa Gz-@Cχ\5 /F( ,o p-UnC>F &JPPP:uj֬Iwb6 7 S*; x=pʁQM{ ldRn߾~&Ym!h"@iKO`gmz'Xbxxxzx{xxx(HAww[TST]X_]PUP]b,,5#=ocXXd.)*5t%zST7 ću'մ^)~'3dA:k [-uGQeFra3 "<]_Z H%vR"m3N .lEzSԾt,MNuQJ^J}R.=D}ۑLÑKm"kmltJNV]Dg*c mzӥGu P*#] iS EH 1(]VJIg)?O)d>E^JE_8s]ҡrdE˶NF$"Ut[]6H~OLH@Ap|@6SO|3ȘYQ;~$SDgIx%.tPXR$ͤ/i RN誡뎑UD"-]婔,ꑽilknRd/hToiկK\+NF{; q@EHyAt9ho#Y#*kT'-FY‡ "`D-xL#4'K," V_SJw%UI+7o\ ~AQLJGJޭ2!(0(bLn!@tne0w~`*H oz0 9C=, JfECr );~++b_`]}B“ s/7+zVp2EKG^1<eXrYLTZ.4R-[&ǽHZZdlE2*-B,R-UNLRR+[ԡÁ(8 [S_ IhF۠I:e/ QoTRϗ#eH: Odlg`ʊ@b^J?)BտU_) 5}L*mi.VI9TBoQD47)4#')"͍I"+L*_0O#*< RE$5\&>*w]D*K&*M=],3I\HuWYv/W}eCp*-=QQtMՏg\*K*%Ĕ\^v{EUzDh=* Kvk\=z@jD# M{:s8ap:Z@4